Do excipient unknowns derail your drug development project? What you don’t know about your excipients might surprise you, and could impact your product. The rational incorporation of excipients into quality-by-design (QbD) can inject robustness into your products and protect them against potential failures.
This webinar reviewed the impact of the new IPEC QbD guide on product development and life-cycle management.
- impact of excipient variability on product performance
- critical material attributes
- excipient criticality during development and life-cycle management
- product and process drift
- special cause variation
- bridging the gap between user and maker expectations
Attendees were able to:
- describe QbD and pharmaceutical formulation development concepts to excipient manufacturers and suppliers,
- understand how changes in pharmaceutical formulation practices, due to the introduction of QbD, impact excipient manufacturers and suppliers,
- recognize what excipient users will likely require when applying QbD principles during product development,
- provide feedback to excipient users and regulatory agencies regarding what may or may not be possible when considering the impact of excipient variability in the application of QbD principles during product development
Dave R. Schoneker
David R. Schoneker is currently an independent consultant, specializing in developing regulatory strategies related to excipients, food additives, color additives used in drug and dietary supplement development. With over 42 years of experience working in these areas, he has developed strong networks with regulatory agencies and pharmacopeias around the world.
David R. Schoneker is currently the President/Owner of Black Diamond Regulatory Consulting, LLC, a consulting firm specializing in providing regulatory and quality consulting for the pharmaceutical, dietary supplement, food and related industries. The firm provides expert advice for difficult problems and training on excipient and food additive regulatory, quality and supply chain concerns.
Prior to August 2019, David R. Schoneker was the Global Regulatory Director – Strategic Relationships at Colorcon, Inc. His responsibilities included global coordination of Colorcon’s worldwide regulatory activities. His expertise has been invaluable in developing market expansion projects to gain regulatory acceptance of Colorcon’s products and components for various target markets. Mr. Schoneker also worked closely with Colorcon’s customers and suppliers to provide regulatory training and advice. From 1995 to 2018 he was Director of Global Regulatory Affairs. Prior to 1995 he was Director of Quality Assurance and Quality Control. He was employed at Colorcon from 1977 until 2019.
Mr. Schoneker has been active in many professional organizations such as AAPS, PQRI, RAPS, ASQ, ACS, AOAC and the Delaware Valley Chromatography Forum. He also is involved with a number of trade organizations such as the International Pharmaceutical Excipients Council (IPEC), the International Association of Color Manufacturers (IACM), the Consumer Health Products Association (CHPA), the International Food Additives Council (IFAC), the Council for Responsible Nutrition (CRN) and the Institute of Food Technologists (IFT).
Mr. Schoneker was the President of IACM in 2019 and has been on the IACM Board for many years. In these roles he coordinated IACM’s international regulatory activities related to Synthetic and Natural colorants for use in foods and drugs and participated as one of IACM’s NGO representatives at the Codex Committee on Food Additives (CCFA) for several years.
Mr. Schoneker was the Chairman of IPEC-Americas during the period 2007-2009 and is currently a member of the Executive Committee. He is now serving as the Vice Chair for Science and Regulatory Policy, where he is actively involved with the development of Regulatory, Safety, Excipient GMP and Supplier Qualification related guidelines to improve Excipient Acceptability, Safety and Global Supply Chain Security. Mr. Schoneker also Co-Chairs IPEC’s QbD/Product Development Committee, Composition Committee and IID Working Group. He also is a member of the Board of Directors of the IPEC Foundation. He is the Global Expansion Coordinator for the IPEC Federation, and has been critically involved in the development of many of the IPEC groups and partnerships around the world.
He has acted as an interface with many international regulatory agencies and pharmacopeias for IPEC-Americas. He previously was the USP Liaison for IPEC-Americas and, for many years, represented them as a member of the United States Pharmacopeial Convention. Mr. Schoneker previously coordinated International Harmonization efforts for IPEC-Americas and participated in the development of IPEC’s Good Manufacturing Practices Guide and Auditing Guide for Bulk Pharmaceutical Excipients.
He has also led IPEC’s efforts in developing guidelines for excipient qualification, significant change notification, and the appropriate use of certificates of analysis. He was involved in the development of several third-party auditing and certification programs and standards, such as EXCiPACT, NSF/ANSI IPEC 363 and the International Pharmaceutical Excipients Auditing, Inc. (IPEA). Additionally, Mr. Schoneker chairs a number of harmonization working groups on various excipients and since 2010, has chaired the Coalition for Rational Implementation of the Elemental Impurity Requirements
Mr. Schoneker has participated in the area of Color Science for many years and is author of the chapter “Coloring Agents for Use in Pharmaceuticals” in the 4th edition of the Enclyclopedia of Pharmaceutical Technologywhich was published in 2013. He has also authored many other excipient regulatory, quality, supplier qualification and safety related papers in various journals and trade magazines.
Chris Moreton, Ph.D.
Dr. Moreton has over thirty years experience in the pharmaceutical industry, mainly as a formulation scientist developing a variety of different dosage forms, but also in QA/QC and Technical Support in excipients and drug delivery. Most recently, he has been responsible for the development of clinical and commercial drug products and associated analytical methods, working with clients, licensing partners and contractors.
Dr. Moreton has authored and co-authored scientific papers, articles and book chapters, and lectured extensively on excipients, drug delivery, preformulation and formulation at universities, training courses and symposia in the U.S., Europe and Japan. He is a past Chair of IPEC-Americas.
Brian AC Carlin, Ph.D.
Brian Carlin is Director QbD/Regulatory at DFE Pharma. He previously worked at FMC, SmithKline Beecham & Richardson Vicks. He is a Fellow of the Royal Pharmaceutical Society, and holds honorary Professorships at DeMontfort University and University of Maryland.
He is the recipient of the 2014 IPEC One World Award for Regulatory Excellence, and the 2012 IPEC Foundation Award for Industry Research Achievement. He is the immediate past chair of the IPEC Americas QbD Committee.
He has a doctorate in Interfacial Rheology from London University, and a degree in Pharmacy from the University of Aston in Birmingham.